News

Farydak is used for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory

The company is manufacturing a commercial-scale powderREV machine following the royalty-bearing commercial license that had a machine purchase deal signed in May last year. Sutro has made a

The company is acquiring InvaGen Pharmaceuticals and Exelan Pharmaceuticals, which had combined sales of more than $225m in the twelve months to June 2015. InvaGen develops, manufactures, markets

IGI Laboratories president and CEO Jason Grenfell-Gardner said: "We believe our current pipeline of twenty-nine submissions, exclusive of our four partnered submissions, pending approval by the FDA now

The previously disclosed September 8, 2015 PDUFA date has been extended by the standard extension period of three months. In response to a recent request from the FDA,

The procedure, in which all five of the patient’s brain metastases were treated, took less than 20 minutes, including setup time using the Brainlab technology. Using the traditional

The product will be marketed by Alvogen in three strengths (4.6 mg/24 hours, 9.5 mg/24 hours, and 13.3 mg/24 hours) with Alvogen being the first filer for the

GBR 830 is an antagonist of OX40, a costimulatory receptor expressed on T cells mediating T cell activation and survival. GBR 830 was found to be well tolerated

The 19,000m2 warehouse will have a capacity of around 17,000 pallets and handle all inbound raw materials meant for Novo Nordisk’s production in Denmark. Currently, Novo Nordisk’s facility